AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with eosinophilic granulomatosis with polyangiitis (“EGPA”).EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues and is the second approved indication for Fasenra.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA).Shares of AstraZe ...